Two Sigma Advisers LP Boosts Stock Position in Natera, Inc. (NASDAQ:NTRA)

Two Sigma Advisers LP increased its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 377,700 shares of the medical research company's stock after purchasing an additional 62,400 shares during the quarter. Two Sigma Advisers LP owned about 0.29% of Natera worth $59,790,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after acquiring an additional 2,036,396 shares during the period. Norges Bank bought a new position in shares of Natera in the fourth quarter valued at approximately $224,040,000. Raymond James Financial Inc. purchased a new position in Natera during the fourth quarter valued at approximately $146,419,000. Finally, Vanguard Group Inc. increased its holdings in Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of several analyst reports. Robert W. Baird raised their price target on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Royal Bank of Canada started coverage on Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Piper Sandler raised their price target on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. Finally, Morgan Stanley boosted their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $182.12.

Natera Trading Up 0.4%

Shares of NTRA stock opened at $153.27 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business has a 50-day moving average of $148.89 and a 200 day moving average of $157.17. The stock has a market capitalization of $20.93 billion, a PE ratio of -87.09 and a beta of 1.79. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter last year, the business earned ($0.56) earnings per share. The business's revenue was up 36.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 6,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the transaction, the insider now directly owns 143,768 shares of the company's stock, valued at approximately $20,600,516.72. The trade was a 4.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the transaction, the chief executive officer now owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. This represents a 30.03% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,436 shares of company stock worth $22,019,079. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.